European Journal of Clinical Pharmacology

, Volume 68, Issue 8, pp 1231–1232 | Cite as

Pharmacokinetic and safety of raltegravir in pregnancy

  • Leonardo Croci
  • Michele Trezzi
  • Maria Pia Allegri
  • Tiziana Carli
  • Silvia Chigiotti
  • Maria Piera Riccardi
  • Barbara Ricciardi
  • Mario Toti
  • Cesira Nencioni
Letter to the Editors

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Public Health Service Task Force (2011) Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://AIDSinfo.nih.gov. Accessed 18 October 2011
  2. 2.
    Public Health Service Task Force (2011) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://AIDSinfo.nih.gov. Accessed 18 October 2011
  3. 3.
    Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A (2009) Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 64:109–117. doi: 10.1093/jac/dkp132 PubMedCrossRefGoogle Scholar
  4. 4.
    McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, Hay P, Sadiq ST (2010) High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 24(15):2416–2418. doi: 10.1097/QAD. 0b013e32833d8a50 PubMedCrossRefGoogle Scholar
  5. 5.
    Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, Antoniou T, Loutfy MR (2010) Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 15:677–680. doi: 10.3851/IMP1558 PubMedCrossRefGoogle Scholar
  6. 6.
    Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, Cauda R, Anzidei G, Cusato M, Regazzi M, Floridia M, Tamburrini E (2010) Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 65(9):2050–2052. doi: 10.1093/jac/dkq264 PubMedCrossRefGoogle Scholar
  7. 7.
    Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51(18):5843–5855. doi: 10.1021/jm800245z PubMedCrossRefGoogle Scholar
  8. 8.
    Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657–63. doi: 10.1124/dmd.107.016196 PubMedCrossRefGoogle Scholar
  9. 9.
    Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2005) Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27(6–7):602–609. doi: 10.1016/j.placenta.2005.05.007 PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Leonardo Croci
    • 1
  • Michele Trezzi
    • 2
  • Maria Pia Allegri
    • 1
  • Tiziana Carli
    • 1
  • Silvia Chigiotti
    • 1
  • Maria Piera Riccardi
    • 1
  • Barbara Ricciardi
    • 1
  • Mario Toti
    • 1
  • Cesira Nencioni
    • 1
  1. 1.Unità Operativa Malattie Infettive, Ospedale MisericordiaGrossetoItaly
  2. 2.Unità Operativa Malattie Infettive, Ospedale Il CeppoPistoiaItaly

Personalised recommendations